News & Events

 

August 26th 2008

- Semafore Broadens Pipeline with Multi-Targeted Kinase Inhibitors

August 26th 2008

- SF1126, Semafore's PI3 Kinase Inhibitor, Found To Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines

June 4th 2008

- Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors

April 14th 2008

- Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma